Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Celtis occidentalis pollen is a non-standardized, allergenic extract derived from the pollen of the common hackberry tree (Celtis occidentalis). [13] It is manufactured and marketed by Jubilant HollisterStier LLC under the brand name 'Pollens - Trees, Hackberry Celtis Occidentalis'. [3, 16] The product was first approved in the United States in 1941 and is used for both the diagnosis (via percutaneous skin testing) and treatment (via subcutaneous immunotherapy) of allergic conditions such as hay fever or rhinitis caused by sensitivity to hackberry pollen. [5, 8] While effective for sensitized individuals, hackberry pollen is generally considered to be less allergenic compared to other tree pollens. [13]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Celtis occidentalis pollen.